Key result
β3 adrenergic agonists reduce organ congestion in severe HF models by reversing Na+-K+ pump inhibition.
Why the study?
To examine if β3 AR-selective agonists in vivo increase myocyte Na+-K+ pump activity and reverse organ congestion in severe heart failure.
Does treatment with β3 adrenergic agonists improve Na+-K+ pump function and reduce organ congestion in severe heart failure?
Does treatment with β3 adrenergic agonists improve Na+-K+ pump function and reduce organ congestion in severe heart failure?
β3 adrenergic agonists may offer a novel therapeutic approach for advanced heart failure by reversing Na+-K+ pump inhibition and reducing congestion.
Hypothesis-generating for β3 agonists in advanced HFrEF; prospective trials needed before clinical adoption.
Background: Abnormally high cytosolic Na + concentrations in advanced heart failure impair myocardial contractility. Stimulation of the membrane Na + -K + pump should lower Na + concentrations, and the β3 adrenoceptor (β3 AR) mediates pump stimulation in myocytes. We examined if β3 AR-selective agonists given in vivo increase myocyte Na + -K + pump activity and reverse organ congestion in severe heart failure (HF). Methods: Indices for HF were lung-, heart-, and liver: body weight ratios and ascites after circumflex coronary artery ligation in rabbits. Na + -K + pump current, I p , was measured in voltage-clamped myocytes from noninfarct myocardium. Rabbits were treated with the β3 AR agonists CL316,243 or ASP9531, starting 2 weeks after coronary ligation. Results: Coronary ligation caused ascites in most rabbits, significantly increased lung-, heart-, and liver: body weight ratios, and decreased I p relative to that for 10 sham-operated rabbits. Treatment with CL316,243 for 3 days significantly reduced lung-, heart-, and liver: body weight ratios and prevalence of ascites in 8 rabbits with HF relative to indices for 13 untreated rabbits with HF. It also increased I p significantly to levels of myocytes from sham-operated rabbits. Treatment with ASP9531 for 14 days significantly reduced indices of organ congestion in 6 rabbits with HF relative to indices of 6 untreated rabbits, and it eliminated ascites. β3 AR agonists did not significantly change heart rates or blood pressures. Conclusions: Parallel β3 AR agonists-induced reversal of Na + -K + pump inhibition and indices of congestion suggest pump inhibition is a useful target for treatment with β3 AR agonists in congestive HF.
No takes yet. Share an insight, caveat, or question.
Fry et al. (2020) studied Severe congestive heart failure (n=52). β3 adrenergic agonists (CL316,243, ASP9531, or mirabegron) vs. Untreated HF (rabbits); none (humans) was evaluated on Indices of organ congestion (lung-, heart-, and liver: body weight ratios and ascites) and Na+-K+ pump current. Treatment with β3 adrenergic agonists reversed Na+-K+ pump inhibition and significantly reduced indices of organ congestion in a rabbit model of severe heart failure, with parallel clinical stabilization observed in a small case series of patients with advanced HFrEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: